Saniona’s CEO to BioStock: “SAN2355 is a highly promising candidate for commercialization”

Saniona has announced significant progress in the preclinical development of the epilepsy drug candidate SAN2355 to treat focal-onset seizures. BioStock talked to CEO Thomas Feldthus to learn more.

Read the full interview with Thomas Feldthus at biostock.se:

https://www.biostock.se/en/2024/10/sanionas-ceo-san2355-is-a-highly-promising-candidate-for-commercialization/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/